To compare cardiovascular effects of dobutamine and dopamine, we administered the two agents at a dose of 10 gpg/kg/min i.v. to two groups of chronically instrumented conscious dogs, beginning 40 minutes after coronary artery occlusion and continuing for 24 hours thereafter. A control group that was given an infusion of 5% dextrose was also studied. During the first 30 minutes of infusion, both dobutamine and dopamine produced similar increases in cardiac output, left ventricular dP/dt and dP/dt/P, without significant changes in heart rate, mean arterial blood pressure or regional myocardial blood flow. At 24 hours, cardiac output and left ventricular dP/dt and dP/dt/P continued to be greater in the dobutamine group than in the control group. The acute positive inotropic effects of dopamine were no longer apparent at 24 hours. Epicardial blood flow in the dobutamine-treated group also was higher than that in the control group. There were, however, no differences between groups in the ischemic-to-nonischemic myocardial blood flow ratio. In addition, infarct size, measured by nitroblue tetrazolium staining, was smaller in the dobutamine group (55 ± 4% of risk zone) than in the dopamine group (76 ± 6%) or the control group (76 + 5%). The dobutamine group also differed from the dopamine group in their plasma catecholamine levels. Arterial plasma concentrations of norepinephrine and epinephrine increased above the postocclusion baseline values only during dopamine infusion by 1.50 ± 0.34 and 0.87 0.32 ng/ml, respectively. Dopamine also caused myocardial release of norepinephrine, as evidenced by a significant transmyocardial gradient (coronary sinus minus arterial difference) of 1.48 + 0.27 ng/mI. The results show that dobutamine increases collateral flow to the ischemic myocardium, enhances left ventricular performance, and reduces infarct size. None of these effects were produced by dopamine under these experimental conditions. The difference between the effects of the two drugs probably is related, at least in part, to the detrimental effects of local myocardial release of norepinephrine by dopamine.
DOBUTAMINE is a cardioselective adrenergic agent that augments myocardial contractility, cardiac output and myocardial blood flow with only minimal changes in heart rate or arterial blood pressure.'-5 It may be used clinically to improve depressed cardiac function without further impairment of oxygen balance or metabolism of the ischemic heart.6`Dobutamine not only improves the global performance of the heart, but also reduces infarct size during acute experimental myocardial infarction.9 These salutary effects probably are causally related to the increase in ischemic myocardial blood flow produced by dobutamine. However, Tuttle'0 showed that a reduction of myocardial necrosis by dobutamine was accompanied not only by an increase in myocardial blood flow, but also by a reduction in the amount of norepinephrine released from cardiac sympathetic fibers that was facilitated after myocardial ischemia. Local release of excessive endogenous norepinephrine is generally thought to be injurious to is-chemic myocardium because it has both /3-receptormediated inotropic and metabolic effects that would increase oxygen consumption, and an at-adrenergic vasoconstrictor effect that would reduce oxygen supply.". 12 Tuttle'0 speculated that this reduction in norepinephrine release may contribute to the protective effect of dobutamine on ischemic myocardium.
Like dobutamine, dopamine is a commonly used inotropic agent. Although dobutamine and dopamine have similar acute cardiac effects,513' '4 it probably is not appropriate to generalize the salutary effects of dobutamine on infarct size to dopamine, because their mechanisms of actions as sympathomimetic amines are different.1l 1'-' Dobutamine acts directly on adrenergic receptors, whereas dopamine exerts its adrenergic action both directly on adrenergic receptors and indirectly by releasing norepinephrine from sympathetic nerve endings. 20 Dopamine's potential action of releasing norepinephrine from the heart is in contrast to the reduction in myocardial release of norepinephrine produced by dobutamine.'0 Therefore, it appears that dopamine may not have the same salutary effects as dobutamine in acute myocardial infarction. Indeed, dopamine has been shown to increase ischemic injury, as measured by epicardial ST-segment elevation. 21 22 The effects of dopamine on infarct size have never been studied.
In the present study, we compared the effects of dobutamine and dopamine on systemic hemodynamics, myocardial blood flow, and infarct size in the conscious dog with acute myocardial infarction.
Methods
Adult beagle dogs that weighed 6.9-17.8 kg were studied in a conscious state. Two to 3 weeks before the experiment, a sterile left thoracotomy was made under anesthesia with i.v. sodium pentobarbital (25 mg/kg) and mechanical ventilation with room air using a Harvard respirator. The heart was exposed and the left anterior descending coronary artery isolated for implantation of a Silastic balloon occluder (3.5 mm i.d.) immediately distal to the first diagonal branch. Normal saline was infused transiently into the balloon, and the amount of saline that caused complete occlusion of the coronary artery was determined. Heparin-filled Tygon catheters (1.02 mm i.d.) were inserted into the main pulmonary artery, left atrium and descending thoracic aorta. The catheters and the occluder tubing were then tunneled through the interscapular space and secured externally at the back of the neck. After the wound was closed, the dog was returned to the animal quarters and given 400,000 U of procaine penicillin and 500 mg of dihydrostreptomycin sulfate (Combiotics, i.m.; Pfizer Pharmaceutical Inc.) daily for 4 days.
On the day of the experiment, the dog was pretreated with subcutaneous morphine sulfate (0.5 mg/kg) and placed in the right decubitus position. The ECG was monitored. Two catheters were then inserted under local anesthesia with 0.5% lidocaine (Xylocaine, Astra Pharmaceutical Products, Inc.) with fluoroscopic guidance. A #7F catheter was inserted into the coronary sinus through an external jugular vein and a high-fidelity transducer-tip catheter (Millar Instruments Inc.) in the left ventricular cavity through a femoral artery. In addition, a peripheral vein in a hindleg was cannulated for drug infusion. Heparin (500 U/ kg) was then administered intravenously.
Measurements and Calculations
The intravascular catheters were connected to Statham P23Db pressure transducers and a Brush 480 eight-channel recorder (Gould, Inc., Instrument System Division). The Millar catheter was also connected to the Brush 480 recorder for measuring left ventricular pressure, and electronically differentiated maximal rate of left ventricular pressure rise (dP/dt). In addition, the ratio of left ventricular dP/dt to a developed left ventricular pressure of 50 mm Hg occurring during isovolumic systole was calculated using a PDP-11/10 minicomputer (Digital Equipment Corporation). Heart rate was calculated from the ECG. Cardiac output was measured by the indocyanine green (Cardio-Green; Hynson, Westcott and Dunning, Inc.) dilution method with a Gilford model 140 cardiac output system (Gilford Instrument Laboratories, Inc.). Stroke volume and total peripheral vascular resistance were calculated using conventional formulas.
Organ blood flows were measured by the radioactive microsphere method. 23 24 Radioactive microspheres (New England Nuclear), 15 + 3 mg in diameter and labeled with cerium-141, tin-113, ruthenium-103, and scandium-46 at a specific activity of 10 mCi/g, were suspended in a 10% dextran solution containing 0.01% Tween-80 and adequately sonicated before use. For flow measurements before coronary artery occlusion, 500,000-750,000 microspheres were injected into the left atrium followed by a 10-ml normal saline flush over a 30-second period; 1-1.5 million microspheres were used after coronary artery occlusion. Arterial reference blood was collected for 90 seconds at a rate of 7.75 ml/min using a Harvard pump beginning 10 seconds before the commencement of microsphere injection. After the experiment, coronary angiography was performed; the dog was given heparin and killed with a lethal dose of a sodium pentobarbital. Organs were removed, cleaned, weighed, and prepared for radioactivity counting. Tissue and blood samples were counted for radioactivity using a Packard gamma spectrometer at window settings corresponding to the peak energies of the nuclides used. The activity of each isotope was corrected for background and crossover activities from other isotopes. Organ blood flow was calculated on the PDP-1 1/10 minicomputer using the reference sample method: organ blood flow (m1l1O0g/min) = (arterial reference blood flow [ml/min] X tissue nuclide activity x 100)/ (arterial reference blood nuclide activity x tissue weight [g]).
Mean aortic blood pressure was divided by organ blood flow to obtain the regional organ vascular resistance.
Blood samples were taken simultaneously from the aorta and coronary sinus for measuring plasma catecholamine concentrations, using a radioenzymatic method. 25 The heart was removed for determination of risk zone and infarct size. The left anterior descending coronary artery was cannulated at the site of the balloon occluder and the left main and right coronary arteries were cannulated through their respective ostia. The heart was then perfused for 15 minutes under a constant pressure of 100 mm Hg with a 1% Monastral Red dye solution (E.I. du Pont, de Nemours & Co., Inc.) into the left anterior descending artery and a 0.5% Monastral Blue dye solution into the other two catheters. The area stained red was considered the "risk region." 26 After staining, the left ventricle, including the interventricular septum, was separated from the rest of the heart and cut transversely into six or seven slices approximately 6-7 mm thick. Each slice was weighed and photographed and immersed in a nitroblue tetrazolium solution for 15 minutes at 37°C. (Nitroblue tetrazolium is a marker for tissue dehydrogenase27 that stains noninfarcted viable tissue blue and leaves infarcted areas unstained.) Both sides of the left ventricular slices were then rephotographed. The risk and infarct zones were planimetered on each photograph, and the percent risk or infarct size relative to the entire slice was determined by averaging the percent values for both the apical and basal sections of that slice. The weight for the risk or infarcted portion of the slice was obtained by multiplying the average percent value and the weight of the slice. The weights for all the slices were than added up to determine the total risk region and infarct size. Finally, left ventricular slices were cut into 42-50 myocardial segments, which were divided into endocardial and epicardial halves. These pieces were then weighed and counted for radioactivity and regional blood flow measurements. Left ventricular transmural segments were grouped into four regions according to their endocardial blood flows determined 40 minutes after coronary artery occlusion. Transmural segments with endocardial blood flow less than 25 ml/100 g/min were designated as severely ischemic. Segments with endocardial blood flows of 25-50 ml/100 g/min and 50-75 mi/100 g/min were designated as moderately ischemic and mildly ischemic, respectively. Areas with flows more than 75 ml/l00 g/ min were considered nonischemic.
Experimental Protocol
Dogs were divided into three groups according to drug assignments: dobutamine (10 ,ug/kg/min), dopamine (10 ,ug/ml/min), and 5% dextrose solution. The drugs were administered randomly to dogs. The rest of the protocols was identical in the three groups.
After a 30-minute control period, the left anterior descending coronary artery was occluded by inflating the previously implanted balloon occluder with a predetermined amount of normal saline. Systemic hemodynamics, including cardiac output, heart rate, aortic blood pressure, left atrial pressure, and left ventricular dP/dt and dP/dt/P, were measured at 5-10-minute intervals during the control period and in the first 40 minutes after coronary artery occlusion. Microsphere organ blood flows and plasma catecholamine levels were measured immediately before and 40 minutes after coronary artery occlusion.
Beginning 40 minutes after coronary artery occlusion, one of the three drug solutions was infused in each group at a rate of 0.19 ml/min for 30 minutes using a Harvard infusion pump. Systemic hemodynamics were again determined at 5-minute intervals; regional blood flows and plasma concentrations of catecholamines were measured at the end of the 30-minute infusion. Thereafter, the dog was continuously administered the same dose of the drugs for an additional 23 hours at a rate of 0.9 ml/hour, using a batteryoperated Sigmamotor mobile infusion pump (Sigmamotor, Inc.) as previously described.9
On the second day, 24 hours after coronary artery occlusion, the left ventricular and coronary sinus catheters were reinserted under local anesthesia, and systemic hemodynamics, regional blood flow, and plasma catecholamine levels were measured again. The amount of the drug delivered from the infusion bag over the experimental period was verified by subtracting the weight of the bag after the infusion from that before the infusion.
Statistical Analysis
The experimental results are given as mean ± SEM. The statistical significance of the difference between the three experimental groups was determined by twoway analysis of variance for independent groups with repeated measures. 28 Dunnett's test29 was used to determine the significance of differences between the preocclusion control and the serial repeated measurements after coronary artery occlusion in each group. The t test was used to analyze the difference between two means; p < 0.05 was considered significant.
Results
Coronary artery occlusion was successfully produced in 31 dogs, as shown by coronary angiography and postmortem examination on the second day of the experiment. All dogs showed evidence of acute myocardial ischemia in the first hour after coronary artery occlusion, including electrocardiographic ST-segment elevation and decreased left ventricular dP/dt. Five dogs were excluded from the study: one dog died shortly after coronary artery occlusion, before the drug infusion, and four dogs died during the drug infusion (two dogs received dobutamine, one dopamine and one 5% dextrose). Eight of the remaining dogs (1 1 ± 1 kg) received dobutamine, eight (12 ± 1 kg) dopamine and 10 (11 ±-1 kg) 5% dextrose.
Systemic Hemodynamics
Acute coronary artery occlusion produced similar changes in systemic hemodynamics in all three groups (figs. 1-3). There was a decrease in cardiac output and left ventricular dP/dt and dP/dt/P, and an increase in heart rate. Mean aortic blood pressure did not change significantly, while total peripheral vascular resistance increased initially but subsequently returned to preocclusion control values.
Figures 1-3 also show the acute effects of dobutamine, dopamine and 5% dextrose on hemodynamic variables during the first 30 minutes of drug infusion. Left ventricular dP/dt and dP/dt/P increased significantly during the infusion of dobutamine and dopamine. Mean aortic blood pressure increased slightly in both groups. Cardiac output also increased slightly above the values before drug infusion ( fig. 4 ), but did not differ significantly from the preocclusion controls. The changes in cardiac output and left ventricular dP/dt and dP/dt/P were of similar magnitude in the two groups ( fig. 4 ). In addition, total peripheral vascular resistance did not change significantly from the preocclusion controls in two groups. Heart rate also did not change significantly from the preocclusion control during dobutamine infusion, but was higher than the control value during dopamine infusion. Dextrose infusion did not affect any of the hemodynamic responses to acute coronary occlusion. Mean left atrial pressure decreased from 4.7 ± 1.0 to 3.4 ± 0.9 mm Hg (p < 0.05) during dobutamine infusion, but did not change significantly during dopamine infusion (6.7 + 1.4 to 7.6 ± 2.2 mm Hg) or 5% dextrose infusion (4.0 ± 1.0 to 3.7 + 0.8 mm Hg). Stroke volume increased only during dobutamine infusion ( however, myocardial blood flow increased markedly and was significantly higher in the dobutamine group 25 in all ischemic epicardial segments and in nonischemic myocardium than in the control group ( fig. 7 ). There 5000 * |was no difference in myocardial blood flow between 50000 T \ 0 I the dopamine group and the control group. exhibited ventricular tachycardia. The ventricular rates ____________________ , were similar in the three groups. Cardiac output did not differ from the preocclusion or preinfusion controls in the dextrose and dopamine groups, but it was higher in o ol6000 So the dobutamine group (figs. 1-3 and 5). Left ventricu-E E lar dP/dt and dP/dtIP fell below the levels seen during & the initial infusion of the drugs in all three groups and 100 I!0 lower than the preocclusion control in the dextrose and dopamine groups. Similary, left ventricular dP/dt de-4000 creased below preocclusion values in the dobutamine group, but left ventricular dP/dt/P did not fall below its preocclusion control ( fig. 1 ). The absolute values of I I left ventricular dP/dt and dP/dt/P were lowest in the 0 10 20 30 40 50 60 70 24 group infused with 5% dextrose ( fig. 3 ). When these MINUTES HRS values at 24 hours of infusion were calculated as a FIGURE 2. Effects of coronary artery occlusion and dopamine percentage of preinfusion controls, the values in the infusion on cardiac output, heart rate, left ventricular dPIdt dobutamine group were significantly higher than those and dPIdtIP, mean aortic blood pressure and total peripheral in the dopamine and control groups ( fig. 5 ). vascular resistance. Format and symbols are as in figure 1 . 
Arterial and Coronary Sinus Plasma Catecholamine Concentrations
Plasma norepinephrine and epinephrine levels increased after coronary artery occlusion in both arterial and coronary sinus blood (table 1) . Subsequent infusions of dobutamine and dextrose did not alter the catecholamine concentrations. In contrast, dopamine significantly increased arterial and coronary sinus concentrations of catecholamines (table 1, fig. 8 ). The increments at 24 hours after coronary artery occlusion, however, were smaller than those found 30 minutes after occlusion. Figure 8 also shows that the difference between coronary sinus and arterial concentrations of norepinephrine was acutely increased only by dopamine, suggesting a net release of norepinephrine from the heart. In contrast, the difference between coronary sinus and arterial concentrations of epinephrine suggests a net uptake in the heart. There were no differences between the three groups. 
Myocardial Infarct Size
There were no differences in the weight of either the left ventricle or the risk zone between the dextrose, dobutamine and dopamine groups (table 2). Infarct size was smaller in the dobutamine group, regardless of whether infarct size was expressed in terms of the actual weight of the infarcted region or as a percentage of the whole left ventricle or of the risk zone.
Regional Blood Flows
Coronary artery occlusion resulted in a decrease in blood flow to kidney, lung, and the splanchnic circulation (table 3) . Dobutamine infusion increased blood flow and decreased vascular resistance in skeletal mus- cle. In contrast, dopamine infusion did not change skeletal muscle blood flow ( fig. 9 ). Instead, dopamine increased blood flow to kidney and adrenal gland, and decreased renal and adrenal vascular resistance. None of these changes occurred in the group receiving 5% dextrose. No significant vascular changes occurred in the splanchnic circulation.
Discussion
The present study confirms our earlier report9 that dobutamine improves global mechanical function of the heart during acute myocardial infarction, and further shows that the beneficial effects on cardiac function persist during dobutamine infusion for 24 hours after the coronary occlusion. These salutary effects of dobutamine are accompanied by increases in blood flow to ischemic epicardium and a reduction in infarct size. Our earlier study0 showed that blood flow increased to ischemic myocardium shortly after dobutamine infusion was started. In the present study, dobutamine did not produce an immediate increase in ischemic myocardial blood flow. It was accompanied by an increase in blood flow to the ischemic epicardium 24 hours after coronary artery occlusion, but when myocardial blood flow began to increase cannot be determined. However, since infarcts are usually completed within 6 hours after coronary artery occlusion,30 it appears likely that the collateral flow must have increased by dobutamine within the first several hours of dobutamine infusion in our study. Later changes in flow are not likely to have significant effects on reducing infarct size. The discrepancy in the timing of onset of myocardial blood flow rise between the two studies probably was related to the different doses. The dose of dobutamine in the present study was only half that in the earlier study. The increase in blood flow to ischemic epicardium in preference to endocardium is consistent with the observation that native collateral vessels are more abundant in the epicardium than in the endocardium.31 Furthermore, dobutamine increased blood flow to both ischemic and nonischemic myocardium, without effects on the ratio of ischemic to nonischemic blood flow. This finding suggests that dobutamine did not cause a "coronary steal" as it increased blood flow to normal myocardium. Thus, the reduction in infarct size by dobutamine appears to be causally related, at least in part, to the increase in collateral flow to ischemic myocardium. The mechanisms by which dobutamine increases collateral flow are not known. Dobutamine has /3-receptor-mediated vasodilator effects.4 In addition, the well-maintained aortic blood pressure in the dobutamine group may have contributed to the relatively higher coronary perfusion pressure for the coronary circulation compared with that of the dextrose group.
Neither coronary sinus norepinephrine concentration nor the transmyocardial (coronary sinus minus aortic) norepinephrine concentration gradient decreased during dobutamine infusion. Our results, how- ever, do not disprove Tuttle's hypothesis'0 that the myocardial salvage by dobutamine may result partly from diminished release of norepinephrine from the ischemic myocardium, because most of the coronary sinus blood came from nonischemic myocardium and only a small fraction from the ischemic region. Significant changes in the amount of norepinephrine released from the ischemic myocardium might have been masked by norepinephrine-containing blood returning from nonischemic regions.
Our results further indicate that unlike dobutamine, dopamine affected neither cardiac function nor ischemic myocardial blood flow 24 hours after coronary arterial occlusion, although the acute cardiovascular effects of dobutamine and dopamine during the initial infusion were similar. Infarct size also was unaffected '4 C'a (3- by dopamine infusion. The changes in plasma catecholamine demonstrate that as expected, dopamine caused a release of endogenous catecholamines from both sympathetic nerves endings and adrenal medulla. In contrast, dobutamine, which, like isoproterenol, has a large N-substituent group,32 is not taken up into the sympathetic nerve endings and does not cause release of endogenous norepinephrine. Dopamine produced a net release of norepinephrine from the heart. Norepinephrine probably was released from both the ischemic and nonischemic myocardium, because tissue norepinephrine was depleted in both of these regions after acute myocardial infarction. 33 This endogenously released norepinephrine may produce a greater vasoconstrictor effect than circulating catecholamines .' Alpha-receptor-mediated vasoconstriction could have limited the increase in myocardial blood flow. 36 In addition, endogenously released norepinephrine may exert deleterious effect on the ischemic myocardium by its oxygen-wasting effects in the'mitochondria, and its actions causing calcium accumulation in the cardiac cell.'1 12 Myocardial cellular damage may be produced in isolated rat heart by even small doses of norepinephrine released by hypoxia or myocardial infarction.37 Furthermore, dopamine increases arterial concentrations of free fatty acids22 'whereas dobutamine does not.4 Since myocardial lipolysis increases myocardial oxygen requirements, these effects of dopamine are detrimental in the setting of acute myocardial ischemia. '2 Earlier studies in anesthetized, open-chest dogs showed that dopamine exaggerated the ischemic injury, as evidenced by epicardial ST-segment elevations.21' 22 On the other hand, our results in conscious dogs indicate that infarct size was not significantly increased by dopamine. This apparent discrepancy may be related in part to the use of anesthesia and open-chest preparations by previous investigators. In addition, epicardial ST-segment elevation was used to detect acute effects of dobutamine in the earlier studies, whereas infarct size was measured 24 hours later in our experiments. Aggravation of ischemic insult during the acute phase of myocardial ischemia might not necessarily produce a greater infarct size in our preparation because the infarct size, as expressed by percent risk zone, was already nearly maximal in' the control dextrose group (76%). 38 Dobutamine improves myocardial mitochondrial ultrastructure in patients with congestive cardiomyopathy.39 This may lead to better mitochondrial use of oxygen and better recovery of depressed cardiac function. The mechanism responsible for these biochemical effects, however, is poorly understood.
CIRCULATION
The diminished inotropic effects of dopamine 24 hours after coronary artery occlusion probably are related to both the loss of viable myocardium and the decrease in tissue catecholamine storage. 33 Dopamine might have enhanced the rate of norepinephrine depletion in the heart. Although depletion of norepinephrine by itself does not necessarily change intrinsic myocardial contractility,33 40 it would attenuate the inotropic response of the heart to indirectly acting adrenergic agents like dopamine.
Dobutamine and dopamine exert different effects on peripheral vasculature. Dobutamine increased skeletal muscle blood flow. In contrast, dopamine increased blood' flow to the kidneys and adrenal glands. The increase in renal blood flow probably is caused by the dopaminergic action of the drug.'6 The increase in adrenal blood flow was accompanied'by increases in plasma catecholamines, suggesting the blood flow re-757 VOL 67, No 4, APRIL 1983 sponse was closely coupled to the adrenal release of catecholamines. The mechanism for this change is not known.
Both dobutamine and dopamine are useful inotropic agents in patients with heart failure. Dobutamine is a preferred agent to improve depressed myocardial performance in patients with low output cardiac failure3 4& and patients with acute myocardial infarction.42 Dobutamine produces favorable effects on hemodynamics in most patients with acute myocardial infarction6 and in heart failure complicating coronary artery disease' without serious deleterious side effects. Nevertheless, dopamine may increase renal perfusion by its unique dopaminergic action, not present with dobutamine. Our present study suggests that dobutamine is more effective than dopamine in producing sustained cardiac improvement after acute myocardial infarction, and that the norepinephrine-releasing property of dopamine may be detrimental to the ischemic myocardium. infarct volume and to compare two CTT methods of assessing myocardial infarct size with autopsy values; we also used CTT to characterize middle left ventricular (LV) chamber dynamics before and after coronary occlusion by prospective ECG gating and evaluated the variability in estimates of cardiac function by prospective ECG gating of CTT images obtained on two different days.
Methods

Experimental Model
Eleven conditioned mongrel dogs (mean weight 28 ± 4 kg) constituted the study population. Each dog was given subcutaneous morphine sulfate, 3 mg/kg, and then anesthetized with i.v. pentobarbital, 25 mg/ kg. Through a left thoracotomy, a hydraulic coronary occluder was placed around the proximal left anterior descending artery, and in four dogs an injection catheter was placed into the left atrial appendage. The catheters were burrowed subcutaneously and externalized. The wound was closed aseptically and the dogs were allowed to recover. Control CTT scans were ob-
